Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Logo for

J. Pharmacol. Exp. Ther. 322 (3): 913-922

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.

NEUROPHARMACOLOGY

Neuroprotective Effect of Protein Kinase C{delta} Inhibitor Rottlerin in Cell Culture and Animal Models of Parkinson's Disease

Danhui Zhang, Vellareddy Anantharam, Arthi Kanthasamy, and Anumantha G. Kanthasamy

Parkinson's Disorder Research Laboratory, Department of Biomedical Sciences, Iowa Center for Advanced Neurotoxicology, Iowa State University, Ames, Iowa

Abstract: Recent studies from our laboratory demonstrated that the protein kinase C (PKC) {delta} isoform is an oxidative stress-sensitive kinase and a key mediator of apoptotic cell death in Parkinson's Disease (PD) models (Eur J Neurosci 18:1387–1401, 2003; Mol Cell Neurosci 25:406–421, 2004). We showed that native PKC{delta} is proteolytically activated by caspase-3 and that suppression of PKC{delta} by dominant-negative mutant or small interfering RNA against the kinase can effectively block apoptotic cell death in cellular models of PD. In an attempt to translate the mechanistic studies to a neuroprotective strategy targeting PKC{delta}, we systematically characterized the neuroprotective effect of a PKC{delta} inhibitor, rottlerin, in 1-methyl-4-phenylpyridinium (MPP+)-treated primary mesencephalic neuronal cultures as well as in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal model of PD. Rottlerin treatment in primary mesencephalic cultures significantly attenuated MPP+-induced tyrosine hydroxylase (TH)-positive neuronal cell and neurite loss. Administration of rottlerin, either intraperitoneally or orally, to C57 black mice showed significant protection against MPTP-induced locomotor deficits and striatal depletion of dopamine and its metabolite 3,4-dihydroxyphenylacetic acid. Notably, rottlerin post-treatment was effective even when MPTP-induced depletion of dopamine and its metabolites was greater than 60%, demonstrating its neurorescue potential. Furthermore, the dose of rottlerin used in neuroprotective studies effectively attenuated the MPTP-induced PKC{delta} kinase activity. Importantly, stereological analysis of nigral neurons revealed rottlerin treatment significantly protected against MPTP-induced TH-positive neuronal loss in the substantia nigra compacta. Collectively, our findings demonstrate the neuroprotective effect of rottlerin in both cell culture and preclinical animal models of PD, and they suggest that pharmacological modulation of PKC{delta} may offer a novel therapeutic strategy for treatment of PD.


Received for publication April 20, 2007. Accepted for publication June 11, 2007.

Address correspondence to: Dr. Anumantha G. Kanthasamy, Parkinson's Disorder Research Laboratory, Department of Biomedical Sciences, 2062 Veterinary Medicine Bldg., Iowa State University, Ames, IA 50011-1250. E-mail: akanthas{at}iastate.edu

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Rottlerin Inhibits Chlamydial Intracellular Growth and Blocks Chlamydial Acquisition of Sphingolipids from Host Cells.
P. Shivshankar, L. Lei, J. Wang, and G. Zhong (2008)
Appl. Envir. Microbiol. 74, 1243-1249
   Abstract »    Full Text »    PDF »
Stimulatory phosphorylation of cAMP-specific PDE4D5 by contractile agonists is mediated by PKC-dependent inactivation of protein phosphatase 2A.
K. S. Murthy and W. Sriwai (2008)
Am J Physiol Gastrointest Liver Physiol 294, G327-G335
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882